m^(6)A甲基化修饰在消化系统恶性肿瘤免疫治疗中的研究进展  

Progress in Research on m6A Methylation Modification in Immunotherapy of Digestive System Malignant Tumors

作　　者：彭晨 李小琴[1] 王德强[1] 陆懿 应乐倩 黄雨朦 PENG Chen;LI Xiaoqin;WANG Deqiang;LU Yi;YING Yueqian;HUANG Yumeng(Department of Oncology,Affiliated Hospital of Jiangsu University,Zhenjiang,Jiangsu Province,212001)

机构地区：[1]江苏大学附属医院肿瘤科,212001

出　　处：《胃肠病学》2022年第8期499-503,共5页Chinese Journal of Gastroenterology

基　　金：镇江市社会发展项目(SH2021068)。

摘　　要：N^(6)⁃甲基腺苷(m^(6)A)作为转录表达的关键调节剂,是真核细胞中最为常见的表观转录组学修饰。通过三大调节因子甲基转移酶、去甲基化酶和结合蛋白的共同调节,m^(6)A在肿瘤的发生、发展中起有重要作用。免疫治疗作为多种晚期恶性肿瘤的一线治疗方案,在许多消化系统恶性肿瘤患者中表现出明显的耐药性。最近的研究证实,m^(6)A甲基化修饰对肿瘤免疫起有重要的调节作用,从而影响肿瘤患者免疫治疗的疗效。本文就m^(6)A甲基化修饰在消化系统恶性肿瘤免疫治疗中的研究进展作一综述。As a key regulator of transcriptional expression,N^(6)⁃methyladenosine(m^(6)A)is the most commonly seen epigenetic transcriptome modification in eukaryotic cells.m^(6)A plays an important role in the occurrence and development of tumor through the joint regulation of three regulatory factors,methyltransferase,demethylase and binding protein.Immunotherapy,as the first⁃line treatment for many advanced malignant tumors,has shown obvious drug resistance in many patients with digestive system malignant tumors.Recent studies have confirmed that m^(6)A methylation modification plays an important regulatory role in tumor immunity,thus affecting the efficacy of immunotherapy in tumor patients.This article reviewed progress in research on m^(6)A methylation modification in immunotherapy of digestive system malignant tumors.

关 键 词：N^(6)⁃甲基腺苷 消化系统肿瘤 免疫疗法 甲基转移酶类 去甲基化酶类 结合蛋白 

分 类 号：R735[医药卫生—肿瘤]